CD20-selective inhibition of CD47-SIRPα “don't eat me” signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab
Here, we report on a novel bispecific antibody-derivative, designated RTX-CD47, with unique capacity for CD20-directed inhibition of CD47-SIRPα “don't eat me” signaling. RTX-CD47 comprises a CD20-targeting scFv antibody fragment derived from rituximab fused in tandem to a CD47-blocking scFv. Si...
Main Authors: | Peter E. van Bommel, Yuan He, Ilona Schepel, Mark A. J. M. Hendriks, Valerie R. Wiersma, Robert J. van Ginkel, Tom van Meerten, Emanuele Ammatuna, Gerwin Huls, Douwe F. Samplonius, Wijnand Helfrich, Edwin Bremer |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2018-02-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2162402X.2017.1386361 |
Similar Items
-
Stimulation of Glioblastoma Proliferation by Macrophages Through CD47/SIRPα
by: Badham, Katelyn
Published: (2017) -
Potential New Cancer Immunotherapy: Anti-CD47-SIRPα Antibodies
by: Lu Q, et al.
Published: (2020-09-01) -
Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα–CD47 innate immune checkpoint
by: Erik Voets, et al.
Published: (2019-12-01) -
Research Progress of CD47-SIRPα Signaling Axis as An Innate Immune Checkpoint in Cancer
by: ZHA Li, et al.
Published: (2018-08-01) -
Defining the role of CD47 and SIRPα in murine B cell homeostasis
by: Kolan, Shrikant S
Published: (2015)